PT-141
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →Central-nervous
system pathway.
PT-141 (Bremelanotide) is a synthetic melanocortin analog that operates centrally rather than peripherally. Where the older generation of arousal-pathway compounds work on vascular tissue, PT-141 binds MC4R in the CNS - a categorically different mechanism with a categorically different research profile.
It is the most-studied centrally-acting compound in arousal-pathway research today, and the standard reference for any protocol designed around the melanocortin axis rather than the vascular one.
| Compound | Bremelanotide (PT-141) |
|---|---|
| Molecular mass | 1025.2 Da |
| Mechanism / research class | Cyclic heptapeptide. MC1R / MC3R / MC4R agonist. |
| Lab handling solvent | 2mL bacteriostatic water for injection (BWI) |
| Resulting concentration | Yields 0.5mg per 0.1mL |
| Supply format | Bremelanotide · 10MG lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
PT-141 (Bremelanotide) operates centrally on MC4R rather than peripherally on vascular tissue - the mechanistic distinction from PDE5-inhibitor research compounds. The most-cited centrally-acting reference in arousal-pathway literature.
- Pfaus JG et al. Bremelanotide and CNS arousal pathways. Eur J Pharmacol. 2007;571(1):42-50. PubMed ↗
Reference clinical literature in male erectile-research populations reports response on validated arousal-research scales, distinct from peripheral PDE5-inhibitor mechanism.
- Diamond LE et al. Bremelanotide for erectile dysfunction. J Sex Med. 2006;3(4):628-638. PubMed ↗
Questions?
We got answers.
Show references
Used in published research.
4.7 / 5
Solid product, fast EU shipping
Ordered PT-141 for a research-protocol pilot. Arrived in 4 days temperature-controlled, vials sealed and properly lyophilized. Reconstituted cleanly in BWI with no haze. Will reorder.
